Abbott Growth Is Dependent On Full Pipeline, Not Xinlay, CFO Says
Executive Summary
Abbott's sales growth predictions for 2006 do not hinge on FDA approval of Xinlay (atrasentan), the company's investigational prostate cancer therapy, Exec VP-Finance and CFO Thomas Freyman said